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Background: Metabolic syndrome (MetS) is associated with increased risks of diabetes and atherosclerotic
cardiovascular disease. Whether central obesity (CeO) is a prerequisite for the diagnosis of MetS in the International
Diabetes Federation (IDF) definition is a substantial issue because it may influence the clinical value of MetS for
predicting subclinical atherosclerosis.
Methods: We investigated the relation between MetS, as defined by the National Cholesterol Education Program–
Adult Treatment Panel (NCEP–ATP) III criteria, and arterial stiffness according to CeO status in 2,560 healthy Korean
subjects who participated in a community-based cohort study. Arterial stiffness was measured using brachial-ankle
pulse wave velocity (baPWV).
Results: The prevalence of MetS was 37%; 84% of MetS subjects had CeO. The prevalence of diabetes was
significantly higher in MetS subjects than in non-MetS subjects (30 vs. 8%, p <0.001). The number of MetS
components was significantly correlated with baPWV (r = 0.311, p <0.001). In a subgroup analysis of MetS subjects,
the prevalence of diabetes was not significantly different in MetS subjects with and without CeO. MetS subjects
without CeO had significantly higher baPWV than those with CeO (1654 ± 315 vs. 1578 ± 270 cm/s, p = 0.002).
Multiple regression models revealed that waist circumference was independently associated with decreased baPWV
in MetS subjects.
Conclusions: Despite the significant correlation between the number of MetS components and arterial stiffness,
there appeared to be an inverse association between CeO and arterial stiffness in MetS subjects. In contrast to the
IDF definition, our findings suggest that CeO is not crucial for the diagnosis of MetS in otherwise healthy Koreans
having multiple metabolic risk factors with respect to subclinical atherosclerosis reflected in arterial stiffness.
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Metabolic syndrome (MetS) is associated with increased
risks of diabetes and atherosclerotic cardiovascular dis-
ease (CVD) [1-3]. The prevalence of MetS is rapidly
increasing worldwide [4,5], and the diagnosis of MetS is
important to identify individuals at high risk for CVD
because MetS is strongly associated with the deve-
lopment of atherosclerotic major cardiovascular (CV)
events [6,7]. Although the pathogenesis of MetS related
to its individual components is complex, central obesity
(CeO) has been considered to be a causative factor of
MetS because it is a predominant component of MetS
[8,9]. Especially, the International Diabetes Federation
(IDF) suggests that CeO, defined by waist circumference
with ethnicity-specific values, is essential for the diagno-
sis of MetS [10]. However, subjects without CeO but
with multiple metabolic abnormalities are not diagnosed
with MetS according to the IDF definition.
MetS is a concept that focuses attention on a constel-
lation of complex, multifactorial health problems for the
prevention of CVD. Although obesity is one of the im-
portant risk factors for the development of CVD [11,12],
several recent studies have reported the phenomenon of
the “obesity paradox” in which obesity is associated with
improved prognoses in patients after the development of
CVD, including acute myocardial infarction (AMI) and
heart failure [13-16]. These results may imply that, in a
healthy population, the primary prevention of CVD
might be more important in non-obese individuals with
multiple CV risk factors. Thus, it is important to identify
the significance of MetS diagnosis in subjects without
CeO with respect to subclinical atherosclerosis in a
relatively healthy population without a previous history
of major CV events.
Arterial stiffness is an important surrogate marker of
subclinical atherosclerosis, and increasing arterial stiffness
represents an increased risk for major adverse CV events
[17,18]. Brachial-ankle pulse wave velocity (baPWV) is a
reproducible index of arterial elasticity and stiffness [19].
Although a previous study reported that MetS is associ-
ated with increased arterial stiffness [20], the association
between MetS and arterial stiffness according to CeO sta-
tus is unknown. Thus, the present study investigated the
relation between MetS and arterial stiffness according to
the presence of CeO in relatively healthy Korean subjects
who participated in health examinations for a community-
based cohort study.
Methods
This is a cross-sectional investigation analyzing data
collected for a prospective cohort study. We used the
data of 2,560 subjects who participated in baseline health
examinations for a community-based cohort study in the
Seoul area between April 2010 and November 2012.Subjects with a previous history of CVD, cerebrovascular
disease, or malignancy were not included in the present
study according to the study protocol.
All blood samples were obtained after an 8-hr fast
and analyzed for glucose, triglycerides, high-density lipo-
protein (HDL) cholesterol, and low-density lipoprotein
(LDL) cholesterol. Weight, height, and waist circumfer-
ence were measured while subjects wore light clothing
and no shoes. Waist circumference was measured at the
midpoint between the iliac crest and the lower border of
the rib cage. Body mass index (BMI) was calculated as
weight (kg) ÷ height (m2). Diabetes was defined as either
fasting glucose ≥126 mg/dL, a referral diagnosis of dia-
betes, or antidiabetic treatment. MetS was defined as the
presence of 3 or more of the following components,
based on the National Cholesterol Education Program–
Adult Treatment Panel (NCEP–ATP) III definition [1]:
(a) CeO based on waist circumference ≥ 90 cm in males
or ≥ 80 cm in females in accordance with the Asia Pacific
World Health Organization guidelines; (b) HDL choles-
terol <40 mg/dL in males or <50 mg/dL in females; (c)
triglycerides ≥150 mg/dL; (d) systolic blood pressure
(SBP) ≥130 mmHg or diastolic blood pressure (DBP)
≥85 mmHg or on antihypertensive treatment; and (e)
impaired fasting glucose, defined as fasting glucose
≥100 mg/dL, or antidiabetic treatment.
All subjects abstained from caffeine-containing food
for at least 45 minutes before the measurement of
baPWV. After all subjects had been resting in the supine
position for at least 5 minutes in a quiet room, blood
pressure and baPWV were measured using an auto-
mated waveform analyzer (Colin VP-2000, Colin Medical
Instruments Corp., Komaki, Japan). Pneumatic cuffs
were wrapped around both upper arms and ankles and
connected to a plethysmographic sensor to determine
the volume pulse waveform. The highest value of baPWV
measured on either side of each patient was used for ana-
lysis. This study was approved by the local ethics commit-
tee of our institution, and informed consent was obtained
from each participant.
Statistical analysis
Continuous variables are expressed as mean ± SD or me-
dians and interquartile range according to the distribu-
tion. Categorical variables are presented as percentages.
Continuous variables were compared using independent
t-test or Mann–Whitney U-test, and categorical vari-
ables were compared using the χ2 test or Fisher’s exact
test, as appropriate. Correlational analysis between the
number of MetS components and baPWV was per-
formed using Pearson’s correlation test. After identifying
the differences in baPWV according to the presence of
MetS, the mean value of baPWV was compared in sub-
jects with MetS according to their CeO status. Univariate
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association between CeO and baPWV in subjects with
MetS. Multiple regression models were analyzed to iden-
tify the independent association between CeO and
baPWV after consecutive adjustment for confounding
risk factors, including age, gender, smoking, heart rate,
serum creatinine, number of MetS components, and
other MetS components in subjects with MetS. Mul-
tiple linear regression analysis for identifying the
association between baPWV and CV risk factors was
performed in subjects with MetS. The forced entry
method was used to enter independent variables into
the multiple regression models. SPSS version 18 (SPSS
Inc., Chicago, IL, USA) was used for all statistical analyses.
All statistical tests were 2-tailed, and p <0.05 was consi-
dered significant.
Results
A flowchart of this study is presented in Figure 1. The
clinical characteristics of the 2,560 participants (60 ±
8 years, 33% men) in this study are shown in Table 1.
The prevalence of MetS was 37%; 84% of subjects with
MetS had CeO that satisfied the IDF definition. The in-
cidence of CeO was significantly higher in subjects with
MetS than in those without MetS (84 vs. 37%, p <0.001)
(Figure 2). The prevalence of diabetes was significantly
higher in subjects with MetS than in those without
MetS (30 vs. 8%, p <0.001). The number of MetS compo-
nents was significantly correlated with baPWV (r = 0.311,
p <0.001) (Figure 3).
Among the subjects with MetS, the prevalence of
diabetes was not significantly different between MetS
subjects with and without CeO. The incidence of current
medications for the treatment of hypertension, dyslipid-
emia, and diabetes was not significantly different be-
tween MetS subjects with and without CeO. However,
the incidence of male gender (62 vs. 32%, p <0.001) andFigure 1 Study flowchart of the present cohort study.smoking (52 vs. 29%, p <0.001) was significantly higher
in MetS subjects without CeO than in those with CeO.
MetS subjects without CeO had significantly higher
baPWV than those with CeO (1654 ± 315 vs. 1578 ±
270 cm/s, p = 0.002) (Figure 4).
Multiple linear regression models were performed to
identify the association between CeO and baPWV in
subjects with MetS. Unadjusted linear regression ana-
lysis showed an inverse association between central
obesity and baPWV in subjects with MetS (B = −76.001,
p <0.001). This inverse association persisted after con-
secutive adjustment for confounding risk factors: age
(B = −88.328, p <0.001); age and gender (B = −85.560,
p <0.001); age, gender, and smoking (B = −85.537, p <
0.001); age, gender, smoking, and heart rate (B = −70.866,
p = 0.001); age, gender, smoking, heart rate, and serum
creatinine (B = −70.392, p = 0.002); age, gender, smoking,
heart rate, serum creatinine, and number of MetS com-
ponents (B = −78.961, p = 0.001); and age, gender, smok-
ing, heart rate, LDL, eGFR, number of MetS components,
and other MetS components (B = −84.231, p = 0.001)
(Table 2).
Multiple linear regression analysis to identify the asso-
ciation between baPWV and CV risk factors was per-
formed in subjects with MetS. Waist circumference (B =
−4.536, p <0.001), age (B = 15.973, p <0.001), heart rate
(B = 6.425, p <0.001), fasting glucose (B = 0.648, p =
0.021), and SBP (B = 9.166, p <0.001) were independently
associated with baPWV in subjects with MetS (Table 3).
Discussion
To the best of our knowledge, the present study provides
the first information on the inverse association between
CeO and arterial stiffness in MetS subjects among a
relatively healthy Korean population without major ad-
verse CV events. In addition, we identified the preva-
lence of diabetes was not significantly different in MetS
Table 1 Baseline characteristics
Characteristics No MetS (NCEP-
ATP III - / IDF -)
(n = 1,608)
MetS (NCEP-ATP III +) P
Total (n = 952) With CeO (IDF +) (n = 804) Without CeO (IDF -) (n = 148)
Age (years) 65 (60, 69) 64 (57, 69) 62 ± 8 61 ± 7 <0.001
Male gender (%) 31 36 32 62* 0.004
Smoking (%) 24 32 29 52* <0.001
BMI (kg/m2) 24.0 ± 2.7 26.4 ± 2.9 26.8 ± 2.8 23.9 ± 1.9* <0.001
Waist circumference (cm) 81 ± 8 89 ± 7 90 ± 7 81 ± 6* <0.001
Heart rate (bpm) 66 ± 9 68 ± 10 68 ± 10 70 ± 11† <0.001
SBP (mmHg) 120 ± 14 128 ± 15 128 ± 15 130 ± 15 <0.001
DBP (mmHg) 72 ± 9 77 ± 10 76 ± 10 79 ± 10† <0.001
Antihypertensive medications (%) 29 66 67 66 <0.001
Total cholesterol (mg/dL) 201 ± 36 197 ± 37 197 ± 37 195 ± 36 0.006
Triglycerides (mg/dL) 94 (71, 118) 136 (103, 186) 164 ± 82 210 ± 80* <0.001
HDL cholesterol (mg/dL) 57 (51, 63) 45 (37, 55) 47 ± 13 41 ± 11* <0.001
LDL cholesterol (mg/dL) 110 (83, 127) 106 (83, 130) 121 ± 34 117 ± 33 0.096
Lipid lowering medications (%) 27 31 31 27 0.034
Creatinine (mg/dL) 0.78 (0.63, 0.95) 0.81 (0.68, 0.93) 0.79 ± 0.19 0.87 ± 0.19* <0.001
Fasting glucose (mg/dL) 121 (105, 137) 125 (108, 143) 109 ± 24 114 ± 27‡ <0.001
Diabetes (%) 8 30 30 30 <0.001
Antidiabetic treatment (%) 7 25 82 84 <0.001
Duration of diabetes (months) 92 (44, 202) 92 (44, 152) 110 ± 85 107 ± 87 0.177
baPWV (cm/s) 1576 (1414, 1760) 1625 (1452, 1864) 1578 ± 270 1654 ± 315† <0.001
Continuous variables are expressed as mean ± SD or median [interquartile]. Categorical variables are presented as percentages. baPWV, brachial-ankle pulse wave
velocity; BMI, body mass index; CeO, central obesity; DBP, diastolic blood pressure; HDL, high-density lipoprotein; IDF, International Diabetes Federation; LDL,
low-density lipoprotein; MetS, metabolic syndrome; NCEP-ATP III, National Cholesterol Education Program-Adult Treatment Panel III; SBP, systolic blood pressure.
*p <0.001 vs. NCEP-ATP III + / IDF +, †p <0.01 vs. NCEP-ATP III + / IDF +, ‡p <0.05 vs. NCEP-ATP III + / IDF +.
Figure 2 Incidence of CeO in subjects with and without MetS.
Won et al. Diabetology & Metabolic Syndrome 2015, 7:3 Page 4 of 9
http://www.dmsjournal.com/content/7/1/3
Figure 3 Correlation between the number of MetS components and baPWV. The error bars represent the standard deviation.
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able to diagnose MetS based on the number of metabolic
abnormalities considering the significant correlation be-
tween the number of MetS components and the progres-
sion of subclinical atherosclerosis that was reflected in
arterial stiffness. However, in contrast with the IDF de-
finition, our results indicate that the diagnosis of MetS
should be necessary in subjects without CeO but with
multiple metabolic risk factors with respect to subclinicalFigure 4 Comparison of baPWV in subjects with MetS according to Catherosclerosis reflected in arterial stiffness in the general
population.
MetS is a concept that focuses attention on complex
multifactorial health problems for the prevention of CVD.
The prevalence of MetS is rapidly increasing worldwide,
and it affects approximately 31% of adults in Korea [21].
This simultaneous clustering of metabolic abnormalities
appears to confer a substantial additional CV risk over
and above the sum of the risk associated with eacheO status. The error bars represent the standard deviation.
Table 2 Multiple regression models for identifying the
association between central obesity and baPWV in
subjects with MetS
baPWV
R2 B SE β P
MetS with CeO
Model 1 0.010 −76.001 24.842 −0.099 <0.001
Model 2 0.191 −88.328 22.480 −0.115 <0.001
Model 3 0.191 −85.560 23.077 −0.111 <0.001
Model 4 0.191 −85.537 23.090 −0.111 <0.001
Model 5 0.257 −70.866 22.208 −0.092 0.001
Model 6 0.258 −70.392 22.207 −0.091 0.002
Model 7 0.260 −78.961 22.741 −0.103 0.001
Model 8 0.285 −84.231 25.272 −0.109 0.001
β, standardized coefficients; B, unstandardized coefficients; baPWV, brachial-
ankle pulse wave velocity; CeO, central obesity; LDL, low-density lipoprotein;
MetS, metabolic syndrome; SE, standard error.
“Other MetS components” refer to the dichotomous variables of HDL
cholesterol, triglycerides, blood pressure, and fasting glucose according to the
NCEP–ATP III criteria.
Model 1: Unadjusted.
Model 2: Adjusted for age.
Model 3: Adjusted for age and male gender.
Model 4: Adjusted for age, male gender, and smoking.
Model 5: Adjusted for age, male gender, smoking, and heart rate.
Model 6: Adjusted for age, male gender, smoking, heart rate, and
serum creatinine.
Model 7: Adjusted for age, male gender, smoking, heart rate, serum creatinine,
and number of MetS components.
Model 8: Adjusted for age, male gender, smoking, heart rate, serum creatinine,
number of MetS components, and other MetS components.
Table 3 Multiple linear regression analysis for identifying
the association between baPWV and CV risk factors in
subjects with MetS
baPWV
B SE β P
R2 = 0.508
Waist circumference −4.536 1.025 −0.117 <0.001
Age 15.973 0.911 0.429 <0.001
Male gender −15.440 25.512 −0.027 0.545
Smoking 18.800 22.330 0.032 0.400
Heart rate 6.425 0.683 0.229 <0.001
Serum creatinine 66.219 44.050 0.046 0.133
Number of MetS components 2.052 11.565 0.005 0.859
Triglycerides 0.115 0.089 0.034 0.198
HDL cholesterol 0.707 0.599 0.032 0.238
Fasting glucose 0.648 0.281 0.057 0.021
SBP 9.166 0.644 0.494 <0.001
DBP 0.169 1.031 0.006 0.870
β, standardized coefficients; B, unstandardized coefficients; baPWV, brachial-
ankle pulse wave velocity; DBP, diastolic blood pressure; HDL, high-density
lipoprotein; MetS, metabolic syndrome; SBP, systolic blood pressure; SE,
standard error.
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promoted as a means for identifying the risk of CVD
development in clinical practice. Although the patho-
genesis of MetS related to the individual components is
not well understood, CeO has been considered to have
a pivotal role in the pathogenesis of MetS [8,9]. In
particular, compared with other definitions of MetS, the
IDF criteria defined CeO as a prerequisite for the diag-
nosis of MetS [10]. However, individuals without CeO
but having multiple metabolic abnormalities are not diag-
nosed with MetS according to the IDF definition. Because
this may influence the clinical usefulness of MetS for the
prevention of CVD, it is an important issue whether CeO
is a prerequisite for the diagnosis of MetS.
Arterial stiffness is a significant surrogate marker of
subclinical atherosclerosis, and increasing arterial stiff-
ness is independently associated with an increased risk
for major adverse CV events [17,18]. Although previous
studies reported that MetS is strongly associated with
subclinical atherosclerosis [20,24], the relation between
MetS and subclinical atherosclerosis according to the
presence of CeO has not been evaluated. In this study,
we evaluated the correlation between the number of
MetS components and arterial stiffness. Then, we com-
pared the arterial stiffness in subjects with MetS defined
by NCEP–ATP III criteria according to their CeO status.
Interestingly, despite the significant correlation between
the number of MetS components and arterial stiffness,
MetS subjects without CeO had significantly increased
arterial stiffness compared to those with CeO. This inverse
association persisted after adjusting for confounding CV
risk factors including other MetS components. Consider-
ing these results, it might be reasonable to diagnose MetS
based solely on the number of metabolic risk factors, but
the diagnosis of MetS might be even more important in
subjects without CeO but with multiple metabolic risk
factors in order to identify individuals at high risk for
CVD. The IDF definition may be helpful for understand-
ing the pathogenesis of MetS because this definition pri-
marily focuses on the predominant characteristic of MetS,
but it is uncertain whether the IDF definition is more effi-
cient for predicting subclinical atherosclerosis in the gen-
eral population compared to other definitions of MetS.
The results of our study might raise an important ques-
tion as to whether CeO should be a prerequisite compo-
nent for the diagnosis of MetS for the prevention of CVD
in the general population.
Clinical features of atypical MetS subjects who are not
accompanied by CeO have not been well known, espe-
cially in Asian populations. Most definitions of MetS are
reasonable, in that the criteria for metabolic abnorma-
lities used to identify individuals with MetS differ ac-
cording to gender and ethnicity. However, other lifestyle
factors strongly related to the development of CVD such
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MetS. The relation between smoking and obesity is not
completely understood, but previous numerous cross-
sectional studies have reported that body weight or BMI
is lower in smokers than in nonsmokers [25-29]. More-
over, smokers weighed less than nonsmokers, and body
leanness increased with the duration of smoking in the
second National Health and Nutrition Examination Sur-
vey study [30]. Although these studies did not evaluate
the association between smoking and CeO, smoking
might have a suppressive effect on CeO considering the
close association among anthropometric indices includ-
ing body weight, BMI, and waist circumference. In the
present study, while the incidence of smoking was sig-
nificantly higher in subjects with MetS than in those
without MetS, MetS subjects without CeO had signifi-
cantly higher incidence of smoking than those with CeO.
Considering these results, further investigation to identify
the impact of smoking on MetS and its individual compo-
nents may be necessary.
Although obesity is significantly associated with the
development of CVD [11,12], an interesting phenome-
non known as the “obesity paradox” has been reported
in patients after the development of CVD. Several stud-
ies reported either an inverse linear or U-shaped associ-
ation between BMI and all-cause mortality in patients
with heart failure [31-33]. This association was also rep-
licated in patients after the event of AMI [15,16,34]. The
exact mechanism by which obesity may improve progno-
ses in patients with heart failure or AMI is unknown.
Moreover, the impact of CeO on prognoses in patients
with major CV complications has not been evaluated des-
pite the significant relationships among anthropometric
indices. However, considering this paradoxical phenome-
non, is note worthy that the primary prevention of major
CVD may need to be emphasized more in high-risk,
otherwise healthy, non-obese subjects who have no
previous history of major adverse CV events. Recently, the
World Health Organization (WHO) strongly recom-
mended that the concept of MetS should be applied in
subjects without established CVD [35]. This community-
based cohort study was performed in subjects who had no
previous history of CVD, cerebrovascular disease, or
malignancy. We identified the clinical features of atypical
MetS subjects who did not have CeO compared to the
typical MetS subjects with CeO, and found that the IDF
definition had a major limitation for predicting subclinical
atherosclerosis compared to the NCEP–ATP III definition
in the present study.
MetS has been promoted as a means of identifying the
risk for type 2 diabetes development. While the patho-
genesis of MetS is not well understood, CeO and insulin
resistance are acknowledged as important causative fac-
tors for the development of MetS [8-10]. It is obviousthat CeO is strongly associated with insulin resistance.
However, despite the substantial increase in the preva-
lence of MetS and type 2 diabetes in Asian population,
the clinical features of type 2 diabetes in Asia are dis-
tinctly different from the features of type 2 diabetes in
other parts of the world; it develops in a much shorter
time, at a younger age, and in subjects with much lower
BMI in Asia [36]. In addition, several studies on the
pathogenesis of type 2 diabetes in Korean subjects re-
ported that impaired insulin secretion was more promin-
ent than insulin resistance, even in people with impaired
glucose tolerance [37,38]. In the present study, the inci-
dence of CeO was significantly higher in subjects with
MetS than in those without MetS, and CeO was a pre-
dominant characteristics in subjects with MetS. Add-
itionally, the prevalence of diabetes was significantly
higher in subjects with MetS than in those without
MetS. However, there was no significant difference in
the prevalence of diabetes according to the presence of
CeO among the MetS subjects. Accordingly, it may be
that CeO is not an essential component for the diagnosis
of MetS with respect to the identification of the risk for
type 2 diabetes development in Asian populations. Con-
sidering that the fasting glucose level was significantly
higher in MetS subjects without CeO than in those with
CeO, and that fasting glucose was independently associ-
ated with increased baPWV in subjects with MetS, dia-
betes might have been less well controlled in MetS
subjects without CeO than in those with CeO in this co-
hort study.
A number of previous studies have reported an inverse
association between obesity and arterial stiffness in youth
or middle age [39-41]. However, there is a paucity of data
on this inverse association in an older population. Here,
we identified an inverse association between CeO and ar-
terial stiffness in relatively older subjects with MetS. Con-
sidering the results of a recent study that showed different
component clusters of MetS revealed varying associations
with arterial stiffness [42], our findings may provide sub-
stantial information on the association between individual
MetS components and subclinical atherosclerosis in an
older general population.
This study has some limitations. First, although the
criteria of MetS might be dependent on ethnicity [43],
the present study included only a Korean population.
However, this might be a unique point for identifying
the limitation of the IDF definition for predicting sub-
clinical atherosclerosis in Asian population. Second, the
impact of MetS on the progression of subclinical athero-
sclerosis might differ somewhat according to age group
[44]. However, no sub-analysis according to age group
was performed because the participants in this cohort
study were relatively older. Third, several previous stud-
ies of Korean population reported that men had higher
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sent study, the incidence of male gender was significantly
higher in MetS subjects without CeO than in those with
CeO, and this may be a clinical characteristic of atypical
MetS subjects who do not have CeO. Although we identi-
fied an inverse association between CeO and baPWV in
MetS subjects after adjusting for gender differences, fur-
ther investigations are necessary to identify the impact
of gender on this inverse association. Lastly, although
the incidence of current medications for the treatment
of hypertension, dyslipidemia, and diabetes was not
significantly different between MetS subjects with and
without CeO, we could not eliminate the possible effects
of underlying medications on subclinical atherosclerosis
because of the observational design of this study. Further
large prospective studies are required to address these
issues.Conclusion
An inverse association between CeO and arterial stiff-
ness was observed in MetS subjects among relatively
healthy Korean populations. This association persisted
after adjusting for confounding CV risk factors. More-
over, the prevalence of diabetes was not significantly
different in MetS subjects with and without CeO. In
contrast to the IDF definition, the diagnosis of MetS
may be important in Korean subjects without CeO but
having multiple metabolic risk factors.
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